Ann: Half Yearly Report and Accounts, page-100

Even though lactoferrin is widely recognised as an inflammatory modulator, I don't think that a small cap co would take the risk to say it is ok for people with lactose intolerance or any other Inflammatory gastrointestinal diseases. I would prefer that Sunnya/ JAT left it to individuals to work out if it is good for their children and to communicate the beneifts to others. Gastrointestinal problems seem too risky to me. They are often misdiagnosed and problems associated with them are hard to characterise accurately. Also there are a range of levels of severity. A slight improvement may not be viewed favourably by consumers. Increased immunity is a safe target to me and is attractive to a wide audience. In my view it is too risky for a company to make specific claims about lactose intolerance in marketing without testing a specific product in trials . Maybe down the track they could look into it or list some of the benefits that research has identified on their website to increase consumer awareness and so they can consider such benefits as a possibility.